Nanoparticles based on polymers modified with pH-sensitive molecular switch and low molecular weight heparin carrying Celastrol and ferrocene for breast cancer treatment

被引:17
|
作者
Qian, Yun [1 ]
Zhang, Jun [2 ]
Xu, Rui [2 ]
Li, Qiang [1 ]
Shen, Qi [2 ]
Zhu, Guofu [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Sch Pharm, 1200 Cailun Rd, Shanghai 201203, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai 200240, Peoples R China
关键词
Celastrol; pH-Responsive nanoparticles; LMWH; DRUG-DELIVERY; UNFRACTIONATED HEPARIN; TUMOR-GROWTH; METASTASIS; ROS; ACTIVATION; THERAPY; NANOPLATFORM; SUPPRESSION; APOPTOSIS;
D O I
10.1016/j.ijbiomac.2021.05.204
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple negative breast cancer (TNBC) metastasis is still one of the obstacles in clinical treatment, while highlyeffective cancer drugs usually cannot be used for their hydrophobicity and comprehensive system toxicity. This study built a kind of pH-sensitive nanoparticles (PP/H NPs) constructed by poly (lactic-co-glycolic acid) modified with beta-cyclodextrin (PLGA-beta-CD), polyethyleneimine grafted with benzimidazole (PEI-BM) and low molecular weight heparin (LMWH) to delivery Celastrol (Cela) and ferrocene (Fc) for breast cancer therapy. PLGA-beta-CD and PEI-BM were synthesized by amidation reaction, the amphipathic polymer nanoparticles with 108.37 +/- 1.02 nm were self-assembled in water. After PP/H NPs treatment, the half maximal inhibitory concentration (IC50) decreased by 91% compared with Cela, and ROS level was also elevated. PP/H NPs led to substantial tumor inhibiting rate (TIR, 65.86%), utilized LMWH to strengthen the anti-metastasis effect of PP/H NPs. PP/H NPs took advantage of exogenous chemotherapeutics and endogenous ROS to inhibit tumor growth, and combined with LMWH to hinder breast cancer metastasis.
引用
收藏
页码:2215 / 2226
页数:12
相关论文
共 50 条
  • [21] Low molecular weight heparin (LMWH) in cancer patients (PTS) carrying brain metastases (BM): A retrospective analysis
    Vitale, Felice
    Priolo, Domenico
    Colina, Paolo
    D' Angelo, Alessandro
    Antonelli, Giovanna
    Giaimo, Valentina
    Parisi, Alessandra
    Cali, Stefania
    Parisi, Alesandra
    Ferrau, Francesco
    ANNALS OF ONCOLOGY, 2006, 17 : 287 - 287
  • [22] LOW MOLECULAR WEIGHT HEPARIN (LMWH) ADMINISTRATION IN CANCER PATIENTS (PTS) CARRYING BRAIN METASTASES: A RETROSPECTIVE ANALYSIS
    Vitale, Felice
    Priolo, Domenico
    Rotondo, Stefano
    Bramanti, Placido
    Antonelli, Giovanna
    Cali, Stefania
    Parisi, Alessandra
    Colina, Paolo
    Ferrau, Francesco
    ANNALS OF ONCOLOGY, 2004, 15 : 117 - 117
  • [23] Facile and simple preparation of pH-sensitive chitosan-mesoporous silica nanoparticles for future breast cancer treatment
    Liu, W. T.
    Yang, Y.
    Shen, P. H.
    Gao, X. J.
    He, S. Q.
    Liu, H.
    Zhu, C. S.
    EXPRESS POLYMER LETTERS, 2015, 9 (12): : 1068 - 1075
  • [24] Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer
    Wang, Huixin
    Zhao, Yongxing
    Wang, Huiyuan
    Gong, Junbo
    He, Huining
    Shin, Meong Cheol
    Yang, Victor C.
    Huang, Yongzhuo
    JOURNAL OF CONTROLLED RELEASE, 2014, 192 : 47 - 56
  • [25] Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin
    Fiorelli, Elisa Maria
    Rossi, Roberta Elisa
    INTERNAL AND EMERGENCY MEDICINE, 2018, 13 (07) : 1089 - 1091
  • [26] A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer
    Kermani, Ali Taghizadeh
    Hosseini, Sare
    Fanipakdel, Azar
    Mashhad, Mona Joudi
    Rezayat, Kambiz Akhavan
    Zardadi, Mahdi
    Gholami, Arezoo
    Javadinia, Seyed Alireza
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 4191 - 4199
  • [27] Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin
    Elisa Maria Fiorelli
    Roberta Elisa Rossi
    Internal and Emergency Medicine, 2018, 13 : 1089 - 1091
  • [28] The results of the use of low molecular weight heparin (LMWH) for prevention and treatment of thrombosis in cancer patients
    Barkagan, ZS
    THROMBOSIS AND HAEMOSTASIS, 1997, : 772 - 772
  • [29] Treatment of deep vein thrombosis in cancer: A comparison of unfractionated and low molecular weight heparin.
    Kakkar, AK
    Breddin, HK
    Kakkar, VV
    Kadziola, ZA
    BLOOD, 2000, 96 (11) : 449A - 449A
  • [30] Treatment with low-molecular-weight heparin negatively effects lung cancer patient survival
    Held, Julia
    Schneider, Marc A.
    Welte, Tobias
    Janciauskiene, Sabina
    Muley, Thomas
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62